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Summary The Korea Acute Myocardial Infarction Registry (KAMIR) was the ﬁrst nationwide,
population-based, multicenter data collection registry in Korea designed to track outcomes
of patients presenting with acute myocardial infarction (AMI). The registry included 51 com-
munity and teaching hospitals and contained data on 14,870 patients through January 2008.
Patients with non-ST-elevation myocardial infarction had a higher prevalence of co-morbiditiesinfarction;
Non-ST-elevation
myocardial infarction
and worse outcome than patients with ST-elevation myocardial infarction after being discharged
from hospital, emphasizing the need for aggressive outpatient management of these patients.
Risk factors and prognosis after AMI were similar to those in other registries from the West. A
number of innovative approaches have been implemented in numerous studies generated by
the KAMIR and have set standards of care for AMI in the Korean population.
© 2010 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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ntroduction
cute myocardial infarction (AMI) remains a major cause of
ortality worldwide, and survivors of AMI are at increased
isk of further cardiovascular events. The present article
escribes characteristics and clinical outcomes of Korean
atients with AMI and reﬂects current practice of AMI man-
gement in Korea, based on analyses of the Korea Acute
yocardial Infarction Registry (KAMIR), the most recent,
argest AMI database in Korea. Launched in November
005, the KAMIR was the ﬁrst nationwide, population-based,
ulticenter data collection registry in Korea designed
o measure outcomes of patients with AMI. The registry
ncluded 51 community and teaching hospitals and con-
ained data on 14,870 patients through January 2008. The
uccess of the KAMIR led to the establishment of the
orea Working Group on Myocardial Infarction (KorMI), a
ubsequent study of the KAMIR, which is an ongoing open-
nded registry that captures data on the complete spectrum
f patients with AMI including long-term clinical follow-
p. The KorMI includes 25,526 individuals as of March
010.
T-elevation versus non-ST-elevation
yocardial infarction
recent study evaluated 1-year clinical outcome of
T-elevation myocardial infarction (STEMI) versus non-ST-
levation myocardial infarction (NSTEMI) in 13,133 patients
nrolled in the KAMIR between November 2005 and Jan-
ary 2008 (70% men, 63± 13 years of age) [1]. Patients with
TEMI (n = 7855) were younger, more likely to be men and
mokers, and had poorer left ventricular function, while
atients with NSTEMI (n = 5278) had a higher prevalence of
hree-vessel and left main diseases with complex lesions,
nd were more likely to have co-morbidities. In-hospital
nd 30-day mortality rates from AMI were 4.9% and 6.2%,
imilar to those in the U.S. [2,3]. The in-hospital mortal-
ty (6.4% vs. 3.8%, p < 0.001) and 30-day mortality (8.5% vs.
.7%, p < 0.001) were higher in patients with STEMI than
n patients with NSTEMI. Similar ﬁndings were observed
n other western studies: in-hospital mortality and 30-day
ortality of 5—5.8% and 7.4% compared to 7—9.3% and
1.1% with STEMI in the GRACE and Euro Heart registries
4,5]. However, the 1-year mortality was not different
etween patients with STEMI and NSTEMI after control-
ing for confounders (12.3% vs. 9.5%, p = 0.32). This is in
eeping with results from other western studies, which
howed long-term outcomes, in contrast to the short-term
utcomes, were similar or worse with NSTEMI [6—10]. In
he GUSTO-IIb trial [8], for instance, the 30-day mortal-
ty was similar in NSTEMI and STEMI (5.7% vs. 6.1%), but
he 1-year mortality was higher in NSTEMI than STEMI
11.1% vs. 9.6%). In the OPERA registry [10], the in-hospital
t
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ortality (4.3% vs. 4.6%) and 1-year mortality (11.6%
s. 9.0%) rates were similar between NSTEMI and STEMI
atients.
isk factors for AMI
ur knowledge of risk factors for AMI is mostly derived
rom studies in western countries and applicability of these
esults to Asians is uncertain. The association between risk
actors and AMI in Korean population was evaluated in a
umber of studies using the KAMIR database.
Kang et al. [11] assessed the relationship between
ntecedent hypertension and clinical outcomes in 7784
atients with AMI in the KAMIR. In-hospital and 1-year
utcomes were worse in hypertensive patients. However,
ntecedent hypertension was not associated with 1-year
ortality. Lee et al. [12] investigated the effects of dia-
etes on clinical outcome following AMI in 2233 patients
ith hypertension. In hypertensive patients with AMI, the
resence of diabetes was associated with worse clinical and
ngiographic features, a higher risk of severe heart failure,
nd higher incidences of in-hospital and 1-year adverse car-
iac events. Li et al. [13] evaluated the impact of prior
erebrovascular disease (CVD) on the clinical characteris-
ics and mid-term clinical outcomes of Korean patients with
MI in the era of drug-eluting stents. Retrospective analysis
f data on 12,914 patients enrolled in the KAMIR showed
hat patients with CVD had worse clinical characteristics
n admission, presented more often with NSTEMI, were less
ikely to receive reperfusion therapy, and had worse clinical
utcome than those without CVD. Lee et al. [14] assessed
he relationship between clinical outcomes after AMI and
enal function by glomerular ﬁltration rate (GFR) in 6834
atients with normal or mildly elevated serum creatinine
oncentrations (≤2mg/dl) included in the KAMIR. The renal
unction was stratiﬁed arbitrarily into 5 groups based on
he GFR (ml/min/1.73m2): normal function (>90.0), pre-
erved function (75.0—89.9), mild dysfunction (60.0—74.9),
oderate dysfunction (45.0—59.9), and severe dysfunction
<45). The rates of mortality and adverse events were
ncreased with declining renal function. After adjustment
ith confounders, severe and moderate renal dysfunction
ere important risk predictors of in-hospital mortality, 6-
onth mortality and adverse events.
Most studies showed higher short- and long-term mortal-
ty after AMI in women compared to men [15—19], primarily
n younger women (<55—60 years). Lee et al. [20] assessed
ender differences in Korean patients with AMI. Thirty-day
linical outcome was worse in women than men both in
TEMI and NSTEMI. In addition, Yoon et al. [21] observed
hat the U.S. National Cholesterol Education Program Adult
reatment Panel (NCEP-ATP) III recommendations [22], the
ost widely used guidelines for the primary prevention of
oronary events, are less reliable in Koreans, particularly in
omen as compared with men.
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It has been suggested that obesity, a risk factor for coro-
nary heart disease, may also be associated with better
outcomes after AMI [23,24]. This ‘‘obesity paradox’’ (the
inverse relationship between BMI and mortality) may be
explained by more aggressive management in obese patients
or by confounding factors such as age and sex [25]. This issue
was also addressed in studies from the KAMIR. Lee et al. [26]
assessed the relation between BMI and waist-to-hip ratio
(WHR) to clinical outcomes in patients with STEMI. There
was no relation between BMI andmortality and contributions
of some potent confounders such as Killip class and left ven-
tricular ejection fraction appeared to be clear. According to
multivariate analysis, only being underweight had an appar-
ent negative impact on prognosis. Kang et al. [27] examined
the effect of BMI on outcome after primary percutaneous
coronary intervention (PCI) in patients with STEMI. Over-
weight and obese patients were younger, had normal left
ventricular ejection fraction, and were more likely to be
men with a higher incidence of hypertension, diabetes, and
hyperlipidemia. Obese STEMI patients treated with primary
PCI were associated with lower mortality, which may be
explained by better use of medical treatment, hemodynamic
stability, and younger age.
Several studies have shown a seasonal pattern of mortal-
ity from AMI, with higher incidence in the winter than the
summer [28—30]. A diurnal variation in AMI has also been
observed with a peak incidence on Mondays [31]. Similar
ﬁndings were observed in studies from the KAMIR. Lee et
al. [32] investigated the association betweenmeteorological
parameters and hospital admissions for AMI in the temperate
and continental climate of Korea. Seasonal variations were
noted for AMI, characterized by winter peak and summer
trough (p < 0.001) and monthly occurrence of AMI was high-
est in January and lowest in October (p < 0.001). There were
signiﬁcant associations between hospital admissions and
meteorological parameters including air temperature, rela-
tive humidity, and sunshine duration particularly in females
and younger patients (<65 years) (p < 0.01). Park et al. [33]
also observed that the periodic variation in the frequency of
AMI in Korean patients showed peak incidence in the early
morning, in January, and in the winter.
Predictors of mortality after AMI
In the KAMIR study [1], predictors of mortality at
1-year were advanced age (≥75 years), ventricular tachy-
cardia/ﬁbrillation during hospitalization, left ventricular
systolic dysfunction, and the presence of multi-vessel dis-
ease. In the GRACE registry [34], predictors of 6-month
post-discharge mortality included advanced age, history of
myocardial infarction, heart failure, or stroke, and devel-
opment of clinically signiﬁcant hospital complications. In
the OPERA registry [10], predictors of 1-year post-discharge
mortality were history of heart failure, advanced age,
untreated dyslipidemia, diabetes, high heart rate on admis-
sion, and low blood pressure on admission.Among risk scores developed to assess short- and long-
term clinical outcomes after AMI, the most widely utilized
are the TIMI and GRACE risk scores for STEMI and NSTEMI
to predict 14—30-day mortality and in-hospital and 6-month
mortality, respectively [35—38]. Kim et al. [39] devised a
v
a
o
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ew risk score to predict in-hospital and 1-year mortality
sing data on 2148 patients with NSTEMI enrolled in the
AMIR: TIMI risk index (17.5—30: 1 point, >30: 2 points),
illip class (II: 1 point, >II: 2 points), and serum creati-
ine (≥1.5mg/dl: 1 point). When compared with the TIMI
nd GRACE scores, this simpliﬁed risk score system had high
nd similar predictive accuracies for in-hospital and 1-year
ortality.
The prevalence of AMI with angiographically normal or
ear-normal (no vessels with ≥50% stenosis) coronary arter-
es varies between 2.6% and 12% [40—42]. Based on the
urrent literature, these patients have a better progno-
is compared to those with obstructive coronary artery
isease [40,43,44]. Kang et al. [45] clariﬁed the clinical
utcome of 372 patients with normal or near-normal coro-
ary arteries registered in the KAMIR. They were younger,
ad lower prevalence of diabetes, and were more likely to
ave a previous angina history, compared to patients with
bstructive coronary artery disease. Thirty-day and 1-year
linical outcomes were similar between patients with nor-
al or near-normal arteries and those with 1- or 2-vessel
isease.
Presentation during off-hours (weekend and 5 p.m. to 7
.m. on weekdays) may delay door-to-balloon time, thereby
eading to worse clinical outcome in patients with AMI.
his causality was demonstrated in a U.S. National Reg-
stry of Myocardial Infarction review of 33,647 patients with
TEMI who underwent primary PCI [46] and a recent study
f approximately 60,000 patients with AMI [47]. In both
tudies, off-hour presentation was associated with higher in-
ospital and 30-day mortality. Interestingly, different results
ere drawn from analyses of patients with AMI in the KAMIR.
ark et al. [33] observed that in patients with STEMI who
nderwent primary PCI, presentation during off-hours was
ot associated with higher in-hospital mortality despite
he longer symptom-to-ﬁrst medical contact and door-to-
alloon times. This may be explained by the ﬁndings from
ubgroup analysis showing that among the patients who were
ligible for primary PCI, 77% of patients visited hospital
ithin 3 h of symptom onset and there was no difference
n either symptom-to-ﬁrst medical contact time or treat-
ent delay according to the time of symptom onset in this
roup. This was also supported by another study from the
AMIR by Song et al. [48], which demonstrated that 30-day
ortality was not increased signiﬁcantly with any increas-
ng delay in door-to-balloon time (4.3% for ≤90min, 4.4%
or >90min; p = 0.94), symptom onset-to-balloon time (3.9%
or ≤240min, 4.8% for >240min; p = 0.41), and symptom
nset-to-door time (3.3% for ≤120min, 5.0% for >120min;
= 0.13), suggesting that the patient prognosis may not
epend on the initial treatment delay with the current pro-
ocols for AMI treatment in Korea.
A number of serum biomarkers are correlated with
dverse outcome in patients with AMI. The two most com-
only used are serum troponins and CK-MB. Plasma B-type
atriuretic peptide (BNP) and N-terminal pro-B-type natri-
retic peptide (NT-proBNP) also appear to have predictive
alue in STEMI and NSTEMI [49—52]. Elevated values are
ssociated with increased mortality, even in patients with-
ut clinical heart failure, after adjustment for age and left
entricular ejection fraction [48—51]. Kwon et al. [53] also
eported that baseline NT-proBNP level (>991 pg/ml) was
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Associated with increased in-hospital mortality in Korean
atients with STEMI who underwent primary PCI (OR 3.70,
5% CI 1.14—12.03, p = 0.030).
urrent treatment strategies for AMI
ecent studies indicate that a routine invasive approach for
igh-risk patients with NSTEMI yields improved outcomes
ompared with a conservative approach [54,55]. However,
or patients who cannot undergo PCI due to poor general
ealth or critical medical conditions, appropriate conserva-
ive treatment may be more important. Jeong et al. [56]
nalyzed data on 924 patients with NSTEMI in the KAMIR
ho were treated with early conservative strategy. Regard-
ess of their risk proﬁle, the rates of in-hospital and 30-day
ortality decreased with intensive pharmacotherapy. In
he multivariate analysis, low pharmacotherapy index (≤4
oints) was an independent predictor of in-hospital mortal-
ty.
Early elective PCI after successful thrombolytic therapy
or STEMI remains a matter of controversy and recommen-
ations from the major society guidelines have come to
onﬂicting conclusions about the value of early elective PCI
57,58]. Sim et al. [59] assessed the beneﬁts and the opti-
al timing of early elective PCI on 383 patients with STEMI
nrolled in the KAMIR who underwent elective PCI within
weeks of successful thrombolytic therapy. There were no
ifferences in the incidences of major bleeding, in-hospital
ortality, and 30-day outcomes among the groups. However,
- and 12-month clinical outcomes were better in patients
ho underwent PCI within 48 h of thrombolytic therapy com-
ared with those who underwent PCI later.
The 2009 focused update of the American College of
ardiology/American Heart Association guidelines for the
anagement of patients with STEMI states that it is reason-
ble to use a drug-eluting stent (DES) as an alternative to a
are-metal stent for primary PCI in STEMI [60]. Previously,
he safety of the ﬁrst-generation DES in AMI was investigated
y Lee et al. [61] on 1541 Korean patients who received
ither sirolimus- or paclitaxel-eluting stents. One- and 6-
onth outcome and the incidence of stent thrombosis were
ow and not different between the two groups. Recently,
im et al. [62] compared clinical outcomes of zotarolimus-
luting stents and sirolimus-eluting stents on 873 patients
ith STEMI enrolled in the KAMIR. The incidence of one-
ear death or MI was similar, but patients who received
irolimus-eluting stents had lower rates of target-lesion
evascularization (HR = 2.16, 95% CI = 1.01—4.59, p = 0.046)
nd composite major adverse cardiac events (HR = 1.52, 95%
I = 1.07—2.16, p = 0.02).
Whether low-molecular-weight heparin (LMWH) is supe-
ior to unfractionated heparin (UFH) in STEMI patients
ndergoing primary PCI remains unclear. Li et al. [63] eval-
ated bleeding complications and clinical outcomes of 3372
atients with STEMI who received enoxaparin combined with
educed dose of UFH (n = 1531) or UFH alone (n = 1841) dur-
ng PCI with DES implantation. The incidences of major
nd minor bleeding events were similar, but patients who
eceived enoxaparin had lower incidences of cardiac death
adjusted OR= 0.55, 95% CI = 0.39—0.77, p < 0.001), total
eath (adjusted OR= 0.50, 95% CI = 0.37—0.68, p < 0.001),
K
M
A
HD.S. Sim et al.
nd total major adverse cardiac events (adjusted OR= 0.77,
5% CI = 0.62—0.95, p = 0.017) at 8 months as compared with
hose who received UFH, suggesting the safety and efﬁcacy
f LMWH as an adjunctive antithrombotic therapy during
rimary PCI.
An initial retrospective study indicated that triple
ntiplatelet therapy by adding cilostazol to the conven-
ional dual antiplatelet therapy may further reduce the
isk of stent thrombosis, particularly in patients who under-
ent high-risk PCI [64]. In a recent study from the KAMIR,
hen et al. [65] evaluated the safety and efﬁcacy of addi-
ional use of cilostazol to dual antiplatelet therapy in 4230
atients with STEMI who underwent DES implantation. Com-
ared with patients who received dual antiplatelet therapy,
atients who received triple antiplatelet therapy had lower
ncidence of in-hospital mortality (adjusted OR= 0.59, 95%
I = 0.36—0.94, p = 0.026) and 8-month mortality (adjusted
R = 0.60, 95% CI = 0.41—0.89, p = 0.010). The incidence of
ajor bleeding was similar between the groups. Subgroup
nalysis showed that patients with older age (>65 years),
emale gender, and diabetes beneﬁted more from the triple
ntiplatelet therapy.
onclusions
atients with AMI in Korea, compared to the West, have sim-
lar risk factors and clinical outcome. Since patients with
STEMI have worse outcome than patients with STEMI in the
ost-discharge period, greater attention should be paid to
he prevention of complications during clinical follow-up of
hese patients along with aggressive control of cardiovas-
ular risk factors. As shown above, the KAMIR has so far
enerated a multitude of published papers and invited high-
roﬁle international conference presentations and has set
tandards of care for AMI in Korea. The success of the KAMIR
as enabled us to benchmark our care and outcomes against
he best cardiac care in the world and improve any areas
e may need to. An AMI patient is in a race against the
lock and each community should develop a STEMI system of
are incorporating transfer protocols for patients who arrive
t STEMI referral centers and quality improvement efforts
f participating hospitals, emergency medical services, and
ealthcare professionals working in a coordinated fashion
o provide timely reperfusion to all STEMI patients. At the
ame time, prospective registries such as the KAMIR or the
orMI should be essential for control and quality assurance
urposes.
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